Geron GERN Stock
Geron Price Chart
Geron GERN Financial and Trading Overview
| Geron stock price | 0.99 USD |
| Previous Close | 1.02 USD |
| Open | 1 USD |
| Bid | 0.84 USD x 100 |
| Ask | 1.13 USD x 100 |
| Day's Range | 0.96 - 1.02 USD |
| 52 Week Range | 0.84 - 2.01 USD |
| Volume | 10.35M USD |
| Avg. Volume | 12.1M USD |
| Market Cap | 640.37M USD |
| Beta (5Y Monthly) | 0.611 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.08 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.5 USD |
GERN Valuation Measures
| Enterprise Value | 471.32M USD |
| Trailing P/E | N/A |
| Forward P/E | 11.044444 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.943948 |
| Price/Book (mrq) | 2.8238637 |
| Enterprise Value/Revenue | 2.167 |
| Enterprise Value/EBITDA | -31.059 |
Trading Information
Geron Stock Price History
| Beta (5Y Monthly) | 0.611 |
| 52-Week Change | -11.30% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 2.01 USD |
| 52 Week Low | 0.84 USD |
| 50-Day Moving Average | 1.21 USD |
| 200-Day Moving Average | 1.41 USD |
GERN Share Statistics
| Avg. Volume (3 month) | 12.1M USD |
| Avg. Daily Volume (10-Days) | 21.49M USD |
| Shares Outstanding | 644.24M |
| Float | 558.08M |
| Short Ratio | 5.43 |
| % Held by Insiders | 0.080% |
| % Held by Institutions | 76.63% |
| Shares Short | 66.95M |
| Short % of Float | 10.39% |
| Short % of Shares Outstanding | 10.39% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1058:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -21.99% |
| Operating Margin (ttm) | -7.20% |
| Gross Margin | 62.51% |
| EBITDA Margin | -6.97% |
Management Effectiveness
| Return on Assets (ttm) | -1.79% |
| Return on Equity (ttm) | -20.12% |
Income Statement
| Revenue (ttm) | 217.52M USD |
| Revenue Per Share (ttm) | 0.33 USD |
| Quarterly Revenue Growth (yoy) | 27.40% |
| Gross Profit (ttm) | 135.99M USD |
| EBITDA | -15175000 USD |
| Net Income Avi to Common (ttm) | -47834000 USD |
| Diluted EPS (ttm) | -0.08 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 286.48M USD |
| Total Cash Per Share (mrq) | 0.45 USD |
| Total Debt (mrq) | 121.23M USD |
| Total Debt/Equity (mrq) | 53.48 USD |
| Current Ratio (mrq) | 6.313 |
| Book Value Per Share (mrq) | 0.352 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -90533000 USD |
| Levered Free Cash Flow (ttm) | -59214248 USD |
Profile of Geron
| Country | United States |
| State | CA |
| City | Foster City |
| Address | 919 East Hillsdale Boulevard |
| ZIP | 94404 |
| Phone | 650 473 7700 |
| Website | https://www.geron.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 258 |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Q&A For Geron Stock
What is a current GERN stock price?
Geron GERN stock price today per share is 0.99 USD.
How to purchase Geron stock?
You can buy GERN shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Geron?
The stock symbol or ticker of Geron is GERN.
Which industry does the Geron company belong to?
The Geron industry is Biotechnology.
How many shares does Geron have in circulation?
The max supply of Geron shares is 644.24M.
What is Geron Price to Earnings Ratio (PE Ratio)?
Geron PE Ratio is now.
What was Geron earnings per share over the trailing 12 months (TTM)?
Geron EPS is -0.08 USD over the trailing 12 months.
Which sector does the Geron company belong to?
The Geron sector is Healthcare.
Geron GERN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Composite Total Return
XCMP
US
|
31344.11 USD — |
-0.38
|
— — | 30976.16 USD — | 31629.69 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12491.48 USD — |
-0.35
|
— — | 12339.28 USD — | 12603.6 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7247.55 USD — |
-2.3
|
— — | 7246.35 USD — | 7373.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7918.99 USD — |
-2.3
|
— — | 7917.68 USD — | 8056.75 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3026.97 USD — |
-1.72
|
— — | 3024.87 USD — | 3065.71 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
